163 related articles for article (PubMed ID: 27264345)
1. Copy-number variation of MCL1 predicts overall survival of non-small-cell lung cancer in a Southern Chinese population.
Yin J; Li Y; Zhao H; Qin Q; Li X; Huang J; Shi Y; Gong S; Liu L; Fu X; Nie S; Wei S
Cancer Med; 2016 Sep; 5(9):2171-9. PubMed ID: 27264345
[TBL] [Abstract][Full Text] [Related]
2. NCAPH is negatively associated with Mcl‑1 in non‑small cell lung cancer.
Xiong Q; Fan S; Duan L; Liu B; Jiang X; Chen X; Xiong C; Tao Q; Wang J; Zhang H; Chen C; Duan Y
Mol Med Rep; 2020 Oct; 22(4):2916-2924. PubMed ID: 32945371
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer.
Guo X; Li D; Wu Y; Chen Y; Zhou X; Wang X; Huang X; Li X; Yang H; Xing J
Lung Cancer; 2015 Feb; 87(2):162-8. PubMed ID: 25576295
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Antiapoptotic MCL-1 Predicts Worse Overall Survival of Patients With Non-small Cell Lung Cancer.
Nakano T; Go T; Nakashima N; Liu D; Yokomise H
Anticancer Res; 2020 Feb; 40(2):1007-1014. PubMed ID: 32014946
[TBL] [Abstract][Full Text] [Related]
5. Identification of miR‑124a as a novel diagnostic and prognostic biomarker in non‑small cell lung cancer for chemotherapy.
Luo P; Yang Q; Cong LL; Wang XF; Li YS; Zhong XM; Xie RT; Jia CY; Yang HQ; Li WP; Cong XL; Xia Q; Fu D; Zeng QH; Ma YS
Mol Med Rep; 2017 Jul; 16(1):238-246. PubMed ID: 28534972
[TBL] [Abstract][Full Text] [Related]
6. The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer.
Chen Z; Wang J; Bai Y; Wang S; Yin X; Xiang J; Li X; He M; Zhang X; Wu T; Xu P; Guo H
Cancer Gene Ther; 2017 Jan; 24(1):20-27. PubMed ID: 27982019
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.
Yang J; Liu H; Wang H; Sun Y
Pathol Res Pract; 2013 Aug; 209(8):490-4. PubMed ID: 23827213
[TBL] [Abstract][Full Text] [Related]
8. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer.
Wang SY; Li Y; Jiang YS; Li RZ
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4092-4097. PubMed ID: 29028091
[TBL] [Abstract][Full Text] [Related]
9. The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients.
Wang S; Wang J; Bai Y; Wang Q; Liu L; Zhang K; Hong X; Deng Q; Zhang X; He M; Wu T; Xu P; Guo H
Cancer Med; 2016 Sep; 5(9):2332-42. PubMed ID: 27465648
[TBL] [Abstract][Full Text] [Related]
10. Gene Characteristics and Prognostic Values of m
Li N; Chen X; Liu Y; Zhou T; Li W
J Healthc Eng; 2021; 2021():2257066. PubMed ID: 34367534
[TBL] [Abstract][Full Text] [Related]
11. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
12. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
13. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer.
Liu J; Ping W; Zu Y; Sun W
Int J Clin Exp Pathol; 2014; 7(9):6040-7. PubMed ID: 25337249
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-153 expression and prognosis in non-small cell lung cancer.
Chen WJ; Zhang EN; Zhong ZK; Jiang MZ; Yang XF; Zhou DM; Wang XW
Int J Clin Exp Pathol; 2015; 8(7):8671-5. PubMed ID: 26339455
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
16. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H
Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer.
Wang M; Li P; Wan R; Liu X
Biomed Pharmacother; 2019 Apr; 112():108590. PubMed ID: 30784913
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells.
Hirai S; Idogawa M; Sumi T; Yamaguchi M; Niki T; Sakuma Y
Biochem Biophys Res Commun; 2022 Nov; 630():24-29. PubMed ID: 36126466
[TBL] [Abstract][Full Text] [Related]
19. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
Boeri M; Milione M; Proto C; Signorelli D; Lo Russo G; Galeone C; Verri C; Mensah M; Centonze G; Martinetti A; Sottotetti E; Pastorino U; Garassino MC; Sozzi G
Clin Cancer Res; 2019 Apr; 25(7):2166-2173. PubMed ID: 30617131
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC.
Liu L; Qu W; Zhong Z
Int J Clin Exp Pathol; 2015; 8(5):5609-13. PubMed ID: 26191272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
